PhD, Biotechnology
University of Cambridge, Cambridge, United Kingdom
BSc, Biochemistry
University of Birmingham, Birmingham, United Kingdom
Sorrel Wolowacz has more than 2 decades of experience in health economics consulting and 3 decades of experience in the health care industry, including health outcomes, clinical research, and product development. Her research experience is in the areas of economic modelling, real-world evidence, health utility estimation, resource use data (collected alongside trials, by medical record abstraction, surveys, or within databases), and formal health technology assessment submissions. Dr. Wolowacz also has experience in various therapeutic areas, including oncology (specifically lung, breast, ovarian, skin, sarcoma, and haematological cancers, targeted therapies as well as tumour-agnostic therapies), cardiovascular, respiratory, liver disease, arthritis, chronic pain, ophthalmology, and dermatology. She has participated in health technology appraisals in several countries, including the United Kingdom (National Institute for Health and Care Excellence and Scottish Medicines Consortium), Ireland (National Centre for Pharmacoeconomics), Australia (Pharmaceutical Benefits Advisory Committee), and Canada (Canadian Agency for Drug and Technologies in Health, Canadian Drug Review).
Dr. Wolowacz is a member of the editorial board for the Journal of Comparative Effectiveness Research and acts as peer reviewer for Pharmacoeconomics, European Journal of Health Economics, American Journal of Clinical Oncology, Value in Health and Therapeutics, and Clinical Risk Management. She was co-chair of the ISPOR Good Research Practices Task Force addressing measurement of health state utility values for economic models in clinical studies and is a member engagement chair for the ISPOR Working Group for Oncology.